Antimicrobial part 4 Flashcards

1
Q

Antiviral Drugs

A

♦Viruses are intracellular parasites

♦The do not have a cell wall or cell membrane and do not carry out metabolic processes

♦They use much of the metabolic processes of the host—very few drugs are selective enough to prevent viral
replication without injuring the infected individual

♦Treating viral illness is further complicated by the fact that symptoms appear late in the course of illness—after the virus has replicated—so drugs that prevent replication are not helpful

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Treating Viral Respiratory Infections

A

♦Viral URIs that can be treated are Influenza A,
influenza B, and RSV
♦Flu vaccine is more effective than trying to treat
the patient after they are infected
♦Antivirals can be helpful when the patient
cannot be immunized OR when there is an
outbreak

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Neuraminidase Inhibitors examples

A

 Oseltamivir—Tamiflu prototype drug

 Zanamivir—Relenza

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Neuraminidase Inhibitors

A

 Effective against flu A and B; they do not interfere with
immune response to the flu vaccines
 Given prior to exposure, these agents prevent
infections and when given 24-48 hours after the
symptoms occur, they modestly decrease the intensity
and duration of the illness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Neuraminidase Inhibitors: MOA

A

• Flu viruses use a certain neuraminidase that it
slotted into the host cell membrane to release newly formed viruses; this enzyme is critical for the virus to live
• These drugs selectively inhibit neuraminidase—this
prevents new virions from being made and prevents
the virus from spreading

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Neuraminidase Inhibitors: Pharmacokinetics

A

• Oseltamivir is dosed orally as a prodrug that is
hydrolyzed by the liver into active form
• Zanamivir is not active orally and is given via inhalation
• Both are eliminated unchanged in the urine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Neuraminidase Inhibitors: ADEs

A

• GI discomfort and nausea
• Symptoms are lessened if taken with food
• Irritation of the respiratory tract from Zanamivir—use
with caution in those with asthma or COPD—
because it can cause bronchospasm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Neuraminidase Inhibitors: Resistance

A

• Mutations of the neuraminidase enzyme
have been identified in adults with either of the
neuraminidase inhibitors
• These mutants are usually less infective and less
virulent than the wild type influenza

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Amantadine Antivirals examples

A

♦Amantadine—Symmetrel [prototype]
♦Rimantadine—Lumazine
♦Spectrum is only Influenza A
♦Due to resistance—Amantadine is not recommended in the US

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Ribavirin

A

Virazole; synthetic guanosine analog
Effective against a broad spectrum of RNA
and DNA viruses
Used in treatment of immunosuppressed
children with RSV
Also effective in chronic Hepatitis C infections
when used with other direct acting antivirals
[DAAs]

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Ribavirin: MOA

A

• Inhibits replication of RNA and DNA viruses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Ribavirin: Pharmacokinetics

A
  • Effective orally and by inhalation
  • Aerosol is used to treat RSV
  • Absorption is increased if the oral drug is taken with a fatty meal
  • Drugs and metabolites are eliminated in the urine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Ribavirin: ADEs

A
  • Ribavirin—dose dependent transient amnesia, elevated bilirubin
  • Aerosol can be safer, but respiratory function in babies can deteriorate quickly after aerosol treatment is started— close monitoring is mandatory
  • Ribavirin is contraindicated in pregnancy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Treating Hepatic Viral Infections

A

vMany different types of viral hepatitis—Hep B [DNA
virus] and Hep C [RNA virus] are the most
common cause of chronic Hep, cirrhosis and hepatocellular cancer

♦In 2019, we only have therapy for these two viral
hepatitis viruses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How is chronic Hep B treated

A

♦Chronic Hep B can be treated with Peginterferon-α-2a injected SQ weekly
♦Oral therapy for chronic Hep B can be with Lamivudine, Adefovir and Tenofovir

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How is chronic hep C treated

A
♦with a combination of direct acting antivirals [DAAs]—based on the genotype of the virus that patient has
♦Ribavirin can be added to the DDAs
to boost the viral response
♦Pegylated interferon is no longer
commonly used for chronic Hep C
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Treating Hepatis B—Interferons

A

-Naturally occurring inducible glycoproteins that interfere with virus to infect the host cells

-Interferons are synthesized by recombinant DNA
technology—α [alpha], ß [beta] and γ [gamma]

-In pegylated formulations—polyethylene glycol has been attached to interferon-α to increase the size of the molecule, and lengthens duration of action and reduces clearance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Hepatitis B—Interferons: MOA

A

• Incompletely understood
• Involves the induction of host cell enzymes that inhibit viral RNA translation—leading to the breakdown of
viral RNAs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Hepatitis B—Interferons: USES

A

• Peginterferon alfa-2a is approved for chronic Hep
B
• Also indicated for treatment of Hep C in combination with other drugs [but no longer common]

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Hepatitis B—Interferons: ADEs

A

• Flu like sx—fever, chills, myalgias, arthralgias, Gi
distress
• Fatigue and mental depression is common
• Dose limiting BM toxicity, severe fatigue, weight loss,
somnolence, thyroiditis often curbs the use of this agent
• HF has been reported

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Hepatitis B—Lamivudine

A

♦Epivir-HBV is a cytosine analog is an inhibitor of both Hep B and HIV reverse transcriptase

♦Must be phosphorylated by host enzymes to active
form

♦Competitively inhibits Hep B RNA-dependent DNA
polymerase

♦Intracellular half-life of the triphosphate is much longer
than its ½ life

♦Rate of HBV resistance is high after long term use—
therefore it is no longer 1st line in treating chronic Hep B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Hepatitis B—Adenovir

A

♦Hepsera is a nucleotide analog that is phosphorylated by cellular kinases to adefovir diphosphate, which is
incorporated into viral DNA

♦This causes termination of chain elongation and prevents replicationof Hep B virus

♦Given once daily; renally excreted via glomerular filtration and tubular secretion

♦Stopping the drug may result in an exacerbation of Hep B

♦Nephrotoxicity can occur with chronic use

♦Use with caution in those with CKD

♦No longer 1st line in treatment of Hep B—as it has lower efficacy than other agents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Hepatitis B—Entecavir

A
 Baraclude is a guanosine nucleoside
analog for the treatment of Hep B
 After intracellular phosphorylation to
triphosphate, it competes with natural
substrate, deoxyguanosine triphosphate,
for viral reverse transcriptase
 Effective against lamivudine-resistant
strains of Hep B; it is dosed once a day
 Excreted unchanged in the urine;
adjustments are needed in those with
CKD
 Avoid use of other agents with renal
toxicity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Treatment of Hepatitis C

A

♦Once Hep C is inside the cell, a viral genome is released from the
nucleocapsid and a Hep C viral polyprotein is translated using the internal
ribosome entry site

♦Core NS3 and NS5a proteins form the replication complex on fat drops and
serve as a scaffold for RNA polymerase to reproduce the viral genome—
which is then packed in an envelope of glycoproteins before noncytolytic
secretion of mature virions

♦DAAs– target NS3/NS4A protease, NS5B polymerase and NS5A involved in
Hep C replication

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
NS3/NS4A Protease Inhibitors
 Viral NS3/NS4A serine protease needed to process single polyprotein encoded by Hep C RNA into active proteins  Without these serine proteins, RNA replication does not occur and the Hep C life cycle is stalled
26
NS3/NS4A Protease Inhibitors examples
```  Paritaprevir + Ritonavir boost  Grazoprevir  Voxilaprevir  Glecaprevir  ADEs—rash, itching, nausea, fatigue, anemia ```
27
NS5B Polymerase Inhibitors
NS5B is only RNA polymerase responsible for Hep V replication and is processed with other Hep C proteins into an individual polypeptide by the viral NS3/NS4A serine protease; these drugs inhibit NS5B
28
NS5B Polymerase Inhibitors examples
Sofosbuvir Dasabuvir ADEs—few; well tolerated
29
NS5A Replication Complex Inhibitors
``` ♦ NS5A is a viral protein necessary for Hep B RNA replication and assembly ↓ This protein forms a membranous web [along with NS4B]— and this web is the platform for virus replication ↓ Ledipasvir ↓ Ombitasvir ↓ Elbasvir ↓ Velpatasvir ↓ Pribrentasvir ↓ Daclatasvir ↓ Many drug interactions due to their metabolism by CYP 450 and pglycoprotein inhibition ```
30
Ribavirin Pearls
 Approved for the treatment of chronic Hep C when used in combination with standard pegylated interferon or with DDAs  Guanosine analogue, improves viral clearance, decreases relapses rates and improves rates of SVR  Adding Ribavirin to a DDA backed regimen is based on Hep C genotype, cirrhosis status, presence of mutation and treatment history  MOA is unknown  This drug is given BID with food, and it is weight based
31
Options for Hepatitis C
♦Elbasvir/grazoprevir [Zepatier] ♦Glecaprevir/pibrentasvir [Mavyret] ♦Paritaprevirritonavir/ombitasvir [Technivie] ♦Pariaprevier/rtionavir/ombitasvir+dasabuvir [Viekira park, Viekira XR] ♦Sofosbuvir + daclatasvir [Sovaldi + Daklinza] ♦Sofosbuvir/ledipasvir [Harvoni] ♦Sofosbuvir/velpatasvir [Epclusa] ♦Sofasbuvir/velpatasvir/voxilaprevir [Vosevi]
32
Acyclovir
``` Zovirax is the prototype antiherpetic drug It covers HSV1, HSV2, VZV and some strains of Epstein-Barr virus DOC in treating HSV encephalitis Most common use is for genital herpes Used to prevent disease to seropositive patients before BMT and post-cardiac transplant patients ```
33
Acyclovir: MOA
• Guanosine analog; monophosphorylated in the cell the HSV-encoded enzymes • Monophosphate analog is converted to triphosphate with competes as a substrate for viral DNA and incorporates in the viral DNA, causing the DNA chain to terminate
34
Acyclovir: Pharmacokinetics
* Iv, oral, topical routes * Topical form has questionable efficacy * Distributes well throughout the body, including CSF * Partially metabolized to an inactive product * Excretion is via the urine from glomerular filtration and tubular secretion * The drug accumulates in those with CKD * The valyl ester, Valacyclovir, has better bioavailability—it is rapidly hydrolyzed to Acyclovir and achieves level comparable to giving IV Acyclovir
35
Acyclovir: ADEs
* Depends on route of administration * Local irritation from topical use * Headache, diarrhea, nausea and vomiting can be seen with oral dosing * Transient renal dysfunction can be seen with high doses or in a dehydrated patient getting the drug IV
36
Acyclovir: Resistance
• Altered or deficient thymidine kinase and DNA polymerases found in some resistance— especially in the immunocompromised • Cross resistance to other agents in the family does occur
37
Cidofovir
Vistide—indicated for CMV retinitis in patients with AIDS Nucleotide analog of cytosine—inhibits viral DNA synthesis Slow elimination of the active intracellular metabolite allows prolonged dosing intervals Given IV—causes renal toxicity; contraindicated in those with pre-existing renal problems and in those on other nephrotoxic drugs Neutropenia and metabolic acidosis occur Oral Probenecid and IV NS are given with Cidofovir to mute the nephrotoxic effect With the introduction of HAART, the incidence of CMV in the immunosuppressed patient has declined as has the use of this drug
38
Foscarnet
It is a pyrophosphate derivative, and does not need activation by viral or cell kinases Used for CMV retinitis in the immunosuppressed and or Acyclovir resistant HSV Works by reversibly inhibiting viral DNA and RNA polymerases Mutation of the polymerase structure is responsible for resistance Poorly absorbed after oral dose; must be given IV Must be given frequently to avoid relapse when plasma levels fall Dispersed throughout the body, >10 % enters the bone matrix, where it slowly disperses ``` ADEs—nephrotoxicity, anemia, nausea, fever; low Ca++ and Mg+ because of chelation; low K+, phosphate abnormalities, seizures, arrhythmias ``` Parent drug is eliminated by glomerular filtration and tubular excretion
39
Ganciclovir
``` Cytovene—analog of Acyclovir that has greater activity for CMV; used in the treatment of CMV retinitis in the immunosuppressed and to prevent CMV in the transplant patient ```
40
Ganciclovir: MOA
``` • Activated through conversion to the nucleoside triphosphate by viral and cell enzymes • Nucleotide inhibits viral DNA polymerase and can be incorporated into the DNA causing chain termination ```
41
Ganciclovir: Pharmacokinetics
``` • Given IV and distributes throughout the body and CSF • Excretion into urine through glomerular filtration and tubular secretion • Accumulates in those with CKD • Valganciclovir, an oral agents—is the valyl ester of Ganciclovir • Valganciclovir [Valcyte] has high oral bioavailability; it hydrolyses rapidly in the liver and intestine after oral dose and obtains high levels of Ganciclovir ```
42
Ganciclovir: ADEs
``` • Severe dose dependent neutropenia • Carcinogenic and teratogenic • BB warning for use in pregnancy ```
43
Ganciclovir: Resistance
``` • Resistant strains of CMV have been seen with low levels of Ganciclovir triphosphate ```
44
Penciclovir and Famciclovir
``` Penciclovir [Denivir]— acyclic guanosine nucleotide derivative active against HSV-1, HSV-2, VZV ``` ``` Given topically; monophosphorylated by viral thymidine kinase and enzymes from nucleoside triphosphate that inhibits HSV DNA polymerase ``` Intracellular ½ life longer than Acyclovir Minimally absorbed after topical use; well tolerated ``` Famciclovir [Famvir]— cyclic analog of 2’- deoxyguaosine is a prodrug that is metabolized to the active Peniciclovir ``` ``` Antiviral spectrum is similar to that of Ganciclovir, and it is approved to treat acute Herpes Zoster, genital HSV infection, and recurrent Herpes labialis ``` Effective orally; ADEs are headache and nausea
45
Trifluridine
Viroptic—fluorinated pyrimidine nucleoside analog that is structurally similar to thymidine ``` Once converted to triphosphate, inhibits the incorporation of thymidine triphosphate into viral DNA and leads to synthesis of defective DNA that causes the virus to stop replicating ``` Active against HSV1, HSV-2, vaccinia Indicated to treat HSV keratoconjunctivitis and recurrent epithelial keratitis Too toxic to use systemically; use is restricted to ophthalmic drops Short ½ mandates frequent administration ADEs—transient irritation of eye; eyelid edema
46
Acyclovir | slide 42
MOA: Virsuses or diseases affected:
47
Amantadine
MOA: Virsuses or diseases affected:
48
Cidofovir
MOA: Virsuses or diseases affected:
49
Famciclovir
MOA: Virsuses or diseases affected:
50
Forcarnet
MOA: Virsuses or diseases affected:
51
Ganciclovir
MOA: Virsuses or diseases affected:
52
Interferon-α
MOA: Virsuses or diseases affected:
53
Lamivudine
MOA: Virsuses or diseases affected:
54
Oseltamivir
MOA: Virsuses or diseases affected:
55
Penciclovir
MOA: Virsuses or diseases affected:
56
Ribavirin
MOA: Virsuses or diseases affected:
57
Rimantadine
MOA: Virsuses or diseases affected:
58
Valacyclovir
MOA: Virsuses or diseases affected:
59
Zanamivir
MOA: Virsuses or diseases affected:
60
Treating Parasites…
``` Amebiasis is an intestinal infection from Entamoeba histolytica This pathogen is endemic in developing countries; transmitted by fecal-oral route from ingesting contaminated food or water Many that are infected have no symptoms, but some can have symptoms ``` Diagnosis is made by isolating amoeba in the feces ``` Because of the chance of invasive disease and being a potential source of infection—therapy is indicated for symptomatic patients and asymptomatic carriers ``` Drugs are classified as luminal, systemic, mixed amebicides according to their site of action
61
Treating Parasites: Luminal agents
Luminal agents—affect the amoeba in the lumen | of the bowel
62
Treating Parasites: Systemic agents
Systemic agents—against the amoeba | in the intestinal wall and liver
63
Treating Parasites: Mixed agents
—work in both the lumen and systemic forms of amebiasis—although luminal concentrations are too low to be used alone
64
Mixed | Amebicides
``` Metronidazole [Flagyl]—prototype drug Nitroimidazole that is DOC to treat amebic infections Can also be used to treat Giardia lamblia, Trichomonas vaginalis, anaerobic cocci, anaerobic Gram – bacilli [Bacteroides], anaerobic Gram + bacilli [Clostridium difficile] ```
65
Metronidazole: MOA
``` • Amoebas possess electron transport proteins; the nitro group of Flagyl is able to serve as an electron acceptor, and forms reduced cytotoxic compounds that cause the death of Entamoeba histolytica ```
66
Metronidazole: Pharmacokinetics
• Completely and rapidly absorbed after oral dose • For amebiasis, it is usually given with a luminal amebicide, such as Iodoquinol [Yodoxin] or Paromomycin—combination therapy increases cure rates to >90% • Distributes well throughout tissues and fluids; levels found in vaginal, seminal, saliva, breast milk and CSF • Metabolized by hepatic oxidation and then glucoronidated • Giving with inducers of CYP 450, such as Phenobarbital, enhances metabolism; inhibitors, such as Cimetidine, prolongs the ½ life • Accumulates in those with liver disease • Parent drug an metabolites are excreted in the urine
67
Metronidazole: ADEs
``` • Nausea • Vomiting • Epigastric distress • Abdominal cramps • Metallic taste • Oral yeast • Neurotoxicity—dizziness, vertigo, paresthesias • If taken with alcohol, a Disulfiram-like reaction can occur ```
68
Tinidazole
Tindamax 2nd generation nitroimidazole—similar to Metronidazole in coverage, ADEs, and drug interactions Used to treat amebiasis, amebic liver abscess, giardiasis and trichomoniasis Is as effective as Flagyl, but more expensive Alcohol should be avoided when using this agent
69
Luminal Amebicides
``` After treatment of invasive intestinal or extraintestinal amebic disease is complete—a luminal agent, Iodoquinol [Yodoxin], Diloxanide furoate or Paromomycin—should be used to treat the asymptomatic colonized state ```
70
Luminal Amebicides examples
Iodoquinol | Paromomycin
71
Iodoquinol
``` • Yodoxin • Halogenated 8- hydroxyquinolone • Amoebicidal against E. histolytica • Effective against luminal trophozoite and cysts • ADEs—rash, diarrhea, doserelated peripheral neuropathy, optic neuritis [rare] ```
72
Paromomycin
``` • Aminoglycoside antibiotic, only effective against luminal forms of E. histolytica—it is not significantly absorbed from the GI tract • Directly amoebicidal; exerts its effect by decreasing the population of intestinal flora • ADEs—GI distress, diarrhea ```
73
Systemic Amebicides
Used for treating extraintestinal amebiasis, such as liver abscess and intestinal wall infections
74
Systemic Amebicides examples
Chloroquine | Dehydroemetine
75
Chloroquine
``` • Aralen • Used with Flagyl to treat liver abscess • Kills trophozoites in liver abscesses, but not useful in luminal amebiasis • After therapy, patient should be given a luminal amebicide • Also effective to treat malaria ```
76
Dehydroemetine
• Alternative to treat amebiasis • Inhibits synthesis by blocking chain elongation • Given IM • Use of this agent is limited—it is a ipecac alkaloid—with toxicity—it has largely been replaced by Metronidazole • ADEs—pain at injection site; nausea, arrhythmias, HF, neuromuscular weakness, dizziness, rash
77
What drug would you give for asymptomatic cyst carriers
Iodoquinol OR Paromomycin
78
What drug would you give for diarrhea/dysentery or extraintestinal
Metronidazole + Iodoquinol OR | Paromomycin
79
What drug would you give for amebic liver abscess
Metronidazole [or Tinidazole] + | Iodoquinol [or Paromomycin]
80
Treating Malaria cause by:
``` Acute infection caused by 5 species of Plasmodium P. Falciparum P. vivax P. malariae P. ovale P. knowlesi ```
81
Treating Malaria
 Transmitted to humans via the bite of the female Anopheles mosquito  Presentation is headache, fatigue, fever, chills and sweats  P. falciparum is the most dangerous and primary cause of severe malaria—causing fulminating disease with high fever, many parasites in the blood and organ system failure; this pathogen can cause capillary obstruction, cerebral malaria, and death within days without treatment
82
Primaquine
```  8 aminoquinoline oral agent that eradicates primary liver forms of Plasmodium and the hypnozoites of recurring malarias [P. vivax; P. ovale]—this is the only agent that prevents relapse of the these strains of the protozoa in the liver  The sexual [gametocytic] form of all plasmodia are destroyed in the blood or are prevented from maturing later in the mosquito, interrupting transmission  This drug does NOT work on the blood from of malaria, and as a result—cannot be used as monotherapy ```
83
Primaquine: MOA
``` • Metabolites act as oxidants that disrupt the metabolic processed of the plasmodia mitochondria • Metabolites are responsible for schizonticidal action as well as hemolysis and methemoglobinemia [toxicities seen] ```
84
Primaquine: Pharmacokinetics
``` • Well absorbed after oral dose • Not concentrated in the tissues • Rapidly oxidized • Which compound causes the schizonticidal activity has not be identified • Minimally excreted in the urine ```
85
Primaquine: ADEs
``` • Drug induced hemolytic anemia in those with G6PD deficiency • Large doses can cause GI distress • Occasional methemoglobinemia • Should not be used during pregnancy • All species can develop resistance to Primaquine ```
86
Chloroquine
Aralen is a synthetic 4-aminoquinolone—backbone of malarial therapy—but is now limited due to P. falciparum resistance—which is present in all malaria endemic areas except some parts of Central America Less effective against P. vivax Used to prophylax against malaria in travelers going to Chloroquine sensitive areas Can be used to treat extra intestinal amebiasis
87
Chloroquine: MOA
``` • Binds to heme, prevents its polymerization to hemozoin • Increased pH and accumulation of heme causes oxidative damage to the phospholipid membranes, leading to lysis of the parasites and the RBC ```
88
Chloroquine: Pharmacokinetics
``` • Rapidly and completely absorbed after oral dose • Very large volume of distribution, concentrates in RBCs, liver, spleen, kidney, lung, melanin containing tissues and WBCs • It hangs around in the RBCs • Drug also penetrates the CNS and crosses the placenta • Dealkylated by the liver mixedfunction oxidase system • Parent drug and metabolites are excreted mainly in the urine ```
89
Chloroquine: ADEs
• At low doses—used in prophylaxis—very few • At higher treatment doses—GI upset, itching, headaches, blurred vision • Dilated eye exam should be done routinely with prolonged use—due to toxicity to the retina • Discoloration of nail beds and mucous membranes can occur with chronic use • Use with caution in those with liver dysfunction, severe GI problems or neurologic disease • Patients with psoriasis or porphyria should NOT take this drug—as it can provoke an acute attach • Can prolong QTc interval, so using it in patients on other drugs that p
90
AtovaquoneProguanil
Malarone—combination agent for Chloroquine resistant strains of P. falciparum—used in the prevention and treatment of malaria for travelers from outside malaria-endemic areas Not routinely used in endemic areas due to the likelihood for emergence of high-level resistance Atovaquone is a hydroxynaphthoquinone with inhibits mitochondrial processes Cycloguanil, the active triazine metabolite of proguanil, inhibits plasmodial dihydrofolate reductase—preventing DNA synthesis Atovaquone can also treat Babesia sp. and Pneumocystis jirovecii Proguanil is metabolized via CYP 450 2C19—known to exhibit a genetic polymorphism causing poor metabolism of the drug in some individuals Take with food or milk to facilitate absorption ADEs—nausea, vomiting, abdominal pain, headache, diarrhea, anorexia and dizziness
91
Mefloquine
``` Lariam—4-methanolquinolone—structurally like quinine Effective agent to prevent all plasmodia, and for treatment when used in combination with an artemisinin derivative for infections from MDR forms of P. falciparum MOA is unknown; widely distributed to tissues ``` Long ½ life—20 days; because of enterohepatic recirculation and its concentration in various tissues Primarily excreted via the bile into the feces ADEs—at high doses—nausea, vomiting, dizziness, hallucinations and depression Because of the potential for neuropsychiatric reactions, this drug is usually reserved for treating malaria when other agents cannot be used EKG abnormalities and cardiac arrest can occur if Lariam taken with Quinine and Quinidine
92
Quinine
```  Alkaloid isolated from the ark of the Cinchona tree  Interferes with heme polymerization, causing death of the RBC form of the plasmodial parasite  Reserved for severe infections and Chloroquine resistant malaria  Usually given with Doxycycline, Tetracycline or Clindamycin ``` TAKEN ORALLY, WELL DISTRIBUTED THROUGHOUT THE BODY ADES—CINCHONISM— NAUSEA, VOMITING, TINNITUS AND VERTIGO ADES ARE REVERSIBLE AND ARE NOT REASONS TO SUSPEND TREATMENT SUSPEND TREATMENT IF HEMOLYSIS OCCURS
93
Artemisinin
Derived from sweet wormwood plant 1 st line for MDR P. falciparum malaria Giving with another antimalarial is recommended to prevent resistance One orally available regimen is Artemisinin + Lumefantrine [used successfully in uncomplicated disease]—Brand name Coartem  Artesunate + Sulfadoxinepyrimethamine, Mefloquine, Clindamycin or others—the antimalarial action of ``` Artemisinin derivatives involves the production of free radicals from cleavage of the drug’s endoperoxide bridge by heme iron in the parasite food vacuole ``` Oral, rectal, IM and IV formulas are available Short ½ life prevents use of these drugs for prevention ADEs—nausea, vomiting, diarrhea, rash has occurred High doses can prolong the QTc interval
94
Pyrimethamine | [Daraprim]
Daraprim—inhibits plasmodial dihydrofolate reductase needed to synthesize tetrahydrofolate—which is needed to make nucleic acids It is a blood schizonticide and astrong sporonticide Not used alone to treat malaria Fixed dosed combinations wit Sulfadoxine ``` Resistance to this combo has developed—so usually given with other agents—Artemisinin derivatives ``` Pyrimethamine + Sulfadoxine used to treat Toxoplasma gondii ``` If megaloblastic anemia occurs with this agent during treatment—it can be reversed with Leucovorin ```
95
Treating Trypanosomiasis
``` African sleeping sickness [Trypanosomiasis] and American Chagas Disease [Trypanosomiasis] are 2 chronic and eventually fatal disease from Trypanosoma ```
96
Pentamidine
``` Pentam or Nebupent Active against many protozoa—African trypanosomiasis from T. brucei gambiense—it is used to treat early stage disease without CNS involvement Can also treat or prevent Pneumocystis jirovecii and can be used to treat Leishmaniasis ```
97
Pentamidine: MOA
``` • T. brucei concentrates the drug by an energydependent high affinity uptake system—resistance occurs if the protozoa cannot concentrate the drug • MOA not fully understood— drug interferes with parasite synthesis of RNA, DNA, phospholipids and proteins ```
98
Pentamidine: Pharmacokinetics
``` • Given IM or IV to treat Trypanosomiasis and pneumonia from P. jirovecii • For prevention of P. jirovecii pneumonia—pentamidine is given via nebulizer • Drug distributes widely and is concentrated in liver, kidney, adrenals, spleen and lungs • It does not enter the CSF— cannot be used for late stage Trypanosomiasis • Drug is not metabolized; excreted very slowly in the urine ```
99
Pentamidine: ADEs
``` • Renal dysfunction, reversible when stopped • Hyperkalemia; low BP, pancreatitis; ventricular arrhythmias; elevated BS ```
100
Suramin
Used in early stage African trypanosomiasis from T. brucei rhodesiense Very reactive and inhibits manyenzymes, especially those involved in metabolism—which seems to be action that kills the trypanocite Given IV Germanin binds to plasma proteins and does not penetrate the blood-brain barrier Long ½ life [>40 days], excreted unchanged in the urine ADEs—rare, but nausea, vomiting, shock and loss of consciousness can be seen Other ADEs—acute urticaria, blepharitis, paresthesias, photophobia, hyperesthesia of the hands and feet; renal insufficiency, but is reversible when drug is stopped Test dose should be given, as acute hypersensitivity has been seen
101
Melarsopro
Trivalent arsenic compound Only agent available to treat late stage African trypanosome infections and those with CNS involvement from T. brucei rhodesiense Drug reacts with enzymes in the organism and the host Given by slow IV; can be irritating to surrounding tissues ``` DOC for CNS infections that have occurred rapidly as the trypanocidal concentrations in the CSF are quite adequate ``` Human readily oxidizes the drug to a nontoxic pentavalent arsenic compound Very short ½ life and is rapidly excreted in the urine Its use is limited by CNS toxicities—reactive encephalopathy, which is fatal in 10 percent Other ADEs—peripheral neuropathy, HTN, liver toxicity, albuminuria Hypersensitivity reactions, febrile reactions can follow injection Hemolysis can occur in those with G6PD deficiency
102
Eflornithine
Irreversible inhibitor of ornithine decarboxylase; inhibiting this enzyme stops polymerases in the parasite and causes cell division to cease IV form is DOC for late stage African trypanosomiasis from T. brucei gambiense Topical Eflornithine [Vaniqa] is used to treat unwanted facial hair in woman Short ½ life requires IV dose to be given frequently Less toxic than Melarsoprol, but can cause anemia, seizures, and temporary hearing loss
103
Nifurtimox
Used to treat T. cruzi [Chagas Disease]—although its use in chronic stage disease has shown variable results Can be used with Eflornithine to treat late stage T. brucei gambiense Undergoes reduction and generates O2 radicals— superoxide and H2O2—that are toxic to the parasite Given orally; extensively metabolized ADEs—common with chronic administration [especially in older patients]—anaphylaxis, dermatitis, GI distress—severe enough to cause weight loss; peripheral neuropathy, dizziness and headache
104
Benznidazole
``` Nitroimidazole derivative with MOA similar to Nifurtimox— but better tolerated for treating Chagas Disease ``` ADEs—dermatitis, peripheral neuropathy, insomnia, anorexia
105
Treating Leishmaniasis
Protozoal infection from many species of genus Leishmaniasis 3 manifestations—cutaneous, mucocutaneous and visceral [in this presentation, the parasite is in the liver, spleen and blood, if not treated, it is fatal] Transmitted b the bite of the infected sandflies ``` For the visceral form—treatment options include IV Amphotericin B, pentavalent antimonials—Na+ Stibogluconate or Meglumine antimoniate + Pentamidine and Paromomycin Miltefosine—only oral agent for visceral disease Choice of drug depends on species of parasite, host factors and local resistance patterns ```
106
Sodium Stibogluconate
``` Pentavalent antimonial is a prodrug which is reduced to active trivalent antimonial compound ``` MOA is not fully understood ``` Not absorbed orally, so must be given IV; distributed into the extravascular compartment ``` Minimal absorption; excreted in the urine ``` ADEs—injection site pain, pancreatitis, elevated LFTs, arthralgias, myalgias, GI distress, cardiac arrhythmias ``` Resistance has been seen to this drug
107
Miltefosine
1 st oral agent for visceral Leishmaniasis Can also be used for cutaneous and mucocutaneous forms MOA is unknown, but it is thought to interfere with phospholipids and sterols in the parasite membrane ADEs—nausea, vomiting, teratogenic; do not use in pregnant women
108
Treating | Toxoplasmosis
One of the most common infections in humans—caused by T. gondii Transmitted to humans from eating inadequately cooked infected meat or accidently ingesting oocysts from cat feces Infected pregnant woman can transmit T. gondii to her fetus
109
Treatment of choice for toxoplasmosis
Treatment of choice—Sulfadiazine + Pyrimethamine Leucovorin given to prevent folate deficiency ↓ If rash occurs, immediately stop Pyrimethamine— because hypersensitivity to this agent can be severe ↓ Pyrimethamine + Clindamycin Trimethoprim/Sulfameth ↓ Trimethoprim/Sulfamethoxazole used to prevent Toxoplasmosis and P. jirovecii in the immunosuppressed
110
Treating Giardiasis
Giardia lamblia commonly diagnosed intestinal parasite Two life cycles •Binucleate trophozoite [4 flagella] •Four nucleate cyst [drug-resistant] Two life cycles Ingestion occurs from fecally contaminated water or food ``` Trophozoites exist in the small intestine Cysts are formed and pass out in feces Many infections are asymptomatic, but those that have symptoms have diarrhea— and it can be very severe, and very serious in those immunosuppressed or frail DOC is Metronidazole orally for 5 days ``` ``` For Giardiasis, Nitazoxanide is given orally for 3 days Albendazole can also treat Giardiasis Paromomycin is used for the pregnant patient ```
111
Anthelmintic Drugs
Nematodes, trematodes and cestodes are 3 major groups of worms Anthelmintic drugs aim for metabolic targets that present in parasite but are absent or different than those of the human
112
Treating Nematodes
Nematodes are long roundworms that cause infections in the intestine, blood and tissues Mebendazole [Emverm] Synthetic benzimidazole; 1st line for whipworms [Trichuris trichiura], pinworms [Enterobius vermicularis], hookworms [Necator americanus; Ancylostoma duodenale] and roundworms [Ascaris lumbricoides]
113
Treating | Nematodes
``` Mebendazole [and all benzimidazoles], act by binding to parasite ß-tubulin and preventing polymerization in the parasite Affected worms are expelled in the feces Do not use in pregnant patient (In certain mass prevention/treatment scenarios this drug and Albendazole can be given in 2nd or 3rd trimester) ```
114
Drugs to treat Nematodes
 Pyrantel pamoate Thiabendazole  Ivermectin [Stromectal]  Diethylcarbamazine
115
 Pyrantel pamoate
```  Effective in roundworms, pinworms and hookworms  Poorly absorbed after oral dose  Acts as a depolarizing, neuromuscular blocking drug  The worms are paralyzed and expulsed in the feces  ADEs– nausea, vomiting and diarrhea ```
116
Thiabendazole
``` Synthetic benzimidazole Potent broad spectrum anthelmintic Use limited to topical treatment of cutaneous larva migrans Has many toxic effects, so not used often ```
117
 Ivermectin [Stromectal]
 DOC to treat cutaneous Larva migrans, Strongyloidiasis and Onchocerciasis  Also used to treat pediculosis [lice] and scabies  Targets glutamate gated Cl- channel receptors— causing paralysis and death of the worm  Orally dosed—does not readily cross blood-brain barrier  Do not use in pregnancy  Killing the larvae I n onchocerciasis can cause a Maxxotti reaction—fever, headache, dizziness, somnolence, low BP—severity depends on the parasite load  Antihistamines and steroids can reduce the symptoms
118
 Diethylcarbamazine
```  DOC for infection with Wuchereria bancrofti, Brugia malayi or Brugia timori  Kills the larvae and has action against the worms  Rapidly absorbed oral dose with food; excreted in the urine  ADEs—fever, nausea, vomiting, arthralgia, headache ```
119
In countries where filariasis is endemic combination of drugs can be used annually as preventative therapy such as
Diethylcarbamazine + Albendazole or Ivermectin + Albendazole **Those suspected of having onchocerciasis should not be given Diethylcarbamazine—it can accelerate night blindness and cause a severe Mazzotti reaction
120
Drugs to Treat Trematodes
Flukes—leaf shaped flatworms that are characterized by the tissues they infect—liver, lung, blood, etc. Praziquantal [Biltricide]
121
Drugs to Treat Trematodes
Praziquantel is DOC for all forms of Schistosomiasis, other trematode infections and cestode infections, such as taeniasis Causes contracture and paralysis of parasites by increasing the permeability of cell wall membrane to Ca++ Rapid absorption after oral dose— should be taken with food
122
Praziquantal [Biltricide]
Extensively metabolized and inactive metabolites are excreted in urine ADEs—dizziness, malaise, headache, GI upset Dexamethasone, Phenytoin, Rifampin, Carbamazepine increase metabolism of this drug; Cimetidine causes increased drug levels Contraindicated for ocular cysticercosis [killing the organism in the eye can call cause irreversible damage]
123
Drugs Used to Treat Cestodes
``` True tapeworms Worms with a flat segmented body and attach to the host’s intestine Tapeworms lack a mouth and a digestive tract ```
124
Niclosamide
Alternative to Praziquantel to treat taeniasis, diphyllobothriasis and other cestodes Inhibits mitochondrial phosphorylation of ADP in the parasite—killing the cestode, but not the ova Laxative is given before the dose to purge the bowel of all dead segments and to enhance digestion and liberation of the ova ETOH should be avoided for 24 hours This agent is no longer available in US, but used successfully worldwide
125
Albendazole
 Albenza  Inhibits synthesis of glucose uptake in nematodes and is effective against most nematodes  Primary action in treating cestodes, such as cysticercosis and hydatid disease [larvae of Echinococcus granulosis]  This agent is effective in treating Microsporidiosis  Drug is erratically absorbed after oral dosing  High fat meal increases absorption Undergoes extensive 1st pass metabolism Active sulfoxide and its metabolites are excreted in the bile If used 1-3 days for nematodes, ADEs are mild— headache and nausea Treatment long term—90 days—for hydatid disease has the risk of liver toxicity and agranulocytosis or pancytopenia [rare] Medical therapy for neurocysticercosis is associated with inflammation of the CNS from the dying parasites— headache, vomiting, fever and seizures